Proteon Therapeutics, Inc. (PRTO) EPS Estimated At $-0.35; Psychemedics Has 0.95 Sentiment

April 17, 2018 - By Richard Conner

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Logo

Analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report $-0.35 EPS on May, 9.They anticipate $0.04 EPS change or 10.26% from last quarter’s $-0.39 EPS. After having $-0.31 EPS previously, Proteon Therapeutics, Inc.’s analysts see 12.90% EPS growth. The stock increased 2.34% or $0.055 during the last trading session, reaching $2.405. About 10,951 shares traded. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has risen 59.38% since April 17, 2017 and is uptrending. It has outperformed by 47.83% the S&P500.

Psychemedics Corp (PMD) investors sentiment decreased to 0.95 in 2017 Q4. It’s down -0.68, from 1.63 in 2017Q3. The ratio dived, as 20 hedge funds opened new and increased positions, while 21 trimmed and sold positions in Psychemedics Corp. The hedge funds in our database now hold: 2.83 million shares, down from 2.91 million shares in 2017Q3. Also, the number of hedge funds holding Psychemedics Corp in top ten positions was flat from 1 to 1 for the same number . Sold All: 6 Reduced: 15 Increased: 14 New Position: 6.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $42.51 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Since December 15, 2017, it had 1 insider buy, and 0 sales for $22,560 activity. $22,560 worth of stock was bought by Burke Steven Keith on Friday, December 15.

Among 8 analysts covering Proteon Therapeutics (NASDAQ:PRTO), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Proteon Therapeutics had 20 analyst reports since November 11, 2015 according to SRatingsIntel. The firm has “Hold” rating by Cowen & Co given on Tuesday, August 8. The firm has “Market Perform” rating by Raymond James given on Wednesday, December 14. The firm earned “Outperform” rating on Thursday, March 15 by Robert W. Baird. On Wednesday, December 14 the stock rating was downgraded by JMP Securities to “Market Perform”. On Thursday, June 22 the stock rating was maintained by Stifel Nicolaus with “Hold”. H.C. Wainwright downgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Friday, March 17. H.C. Wainwright has “Neutral” rating and $3 target. Maxim Group initiated Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Thursday, November 10. Maxim Group has “Buy” rating and $19 target. As per Wednesday, August 16, the company rating was maintained by Oppenheimer. Raymond James upgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Wednesday, October 26 to “Strong Buy” rating. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, December 14.

Investors sentiment increased to 1.57 in Q4 2017. Its up 0.43, from 1.14 in 2017Q3. It improved, as 2 investors sold Proteon Therapeutics, Inc. shares while 5 reduced holdings. 6 funds opened positions while 5 raised stakes. 7.22 million shares or 1.05% more from 7.15 million shares in 2017Q3 were reported. 2.02 million were reported by Abingworth Llp. Panagora Asset Mgmt Inc reported 15,441 shares stake. Geode Capital Mgmt Lc invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). 38,686 are held by Drw. Renaissance Tech Ltd reported 201,500 shares stake. Counselors Inc has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 50,000 shares. Mpm Asset Ltd Liability Corporation has 983,381 shares. Blackrock Inc accumulated 0% or 4,874 shares. Moreover, Kornitzer Capital Mgmt Ks has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Raymond James Svcs Advsr has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 12,300 shares. Vanguard Grp invested in 210,374 shares or 0% of the stock. Dimensional Fund Advsr Ltd Partnership holds 0% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 18,561 shares. Northern Trust Corp has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Baker Bros Advsrs Limited Partnership owns 298,591 shares. Prelude Capital Management Limited Liability holds 4,947 shares or 0% of its portfolio.

The stock increased 0.34% or $0.07 during the last trading session, reaching $20.9. About 4,454 shares traded. Psychemedics Corporation (PMD) has risen 1.89% since April 17, 2017 and is uptrending. It has underperformed by 9.66% the S&P500.

Psychemedics Corporation (NASDAQ:PMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts